CyberloQ (CLOQ) signs 12‑month Relevate AI licensing and commission pact

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

CyberloQ Technologies entered into a material agreement with Relevate AI to integrate CyberloQ’s multi-factor security protocol as an authentication option within Relevate’s platform.

Under the agreement, Relevate will pay CyberloQ a monthly license fee of $750 plus a 10% commission on each user. Relevate’s platform pricing is $50 per user per month, which translates to a $5 commission to CyberloQ for closed sales opportunities it initiates. CyberloQ will also pay Relevate a 10% commission on sales opportunities CyberloQ closes that were initiated through Relevate. The agreement runs for twelve months, after which both parties will review and decide whether to continue.

8-K Event Classification

Item 1.01 — Entry into a Material Definitive Agreement

1 item

Item 1.01 Entry into a Material Definitive Agreement Business

The company signed a significant contract such as a merger agreement, credit facility, or major partnership.

Understanding 8-K Material Events →

02/26/2026 - 04:40 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) February 26, 2026

CYBERLOQ TECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter)

Nevada

(State or other jurisdiction of incorporation)

000-56264

26-2118480

(Commission

File Number)

(IRS Employer

Identification No.)

4837 Swift Road Suite 210-1, Sarasota, FL		34231
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code (612) 961-4536

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		CLOQ		OTCQB

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01. Entry into a Material Definitive Agreement.

On February 26, 2026, CyberloQ Technologies, Inc., a Nevada corporation (the “Company”) entered into an agreement with Relevate AI (“Relevate”) to integrate the features of CyberloQ® and its multi-factor security protocol into Relevate’s Platform as an authentication option. Relevate shall pay CyberloQ a monthly license fee of $750 per month plus a 10% commission per user. Relevate’s pricing is $50 per user per month, per user for Relevate’s platform, which would result in a $5 commission for any closed sales opportunities initiated through CyberloQ. In addition, Relevate shall receive a 10% commission on any sales opportunities CyberloQ closes with customers for opportunities initiated through Relevate. The term of the agreement is for twelve months, after which the parties will review the arrangement and decide whether to continue the agreement.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	CYBERLOQ TECHNOLOGIES, INC. (Registrant)

	By:	/s/ Christopher Jackson
		Christopher Jackson, President

Date: February 26, 2026

Source: View Original Filing on SEC EDGAR

FAQ

What agreement did CyberloQ Technologies (CLOQ) enter into with Relevate AI?

CyberloQ Technologies entered into a twelve-month agreement with Relevate AI to integrate CyberloQ’s multi-factor security protocol as an authentication option within Relevate’s platform, creating a licensed, recurring revenue and commission-sharing arrangement between the two companies.

How will CyberloQ Technologies (CLOQ) be compensated under the Relevate AI agreement?

CyberloQ will receive a $750 monthly license fee from Relevate AI plus a 10% commission per user. With Relevate’s pricing at $50 per user per month, CyberloQ earns a $5 commission on each closed sales opportunity it initiates through Relevate’s platform.

What commissions will Relevate AI receive in its agreement with CyberloQ Technologies (CLOQ)?

Relevate AI will receive a 10% commission on any sales opportunities that CyberloQ closes with customers when those opportunities were initiated through Relevate. This creates a reciprocal commission structure linked to which party originates the customer opportunity.

What is the term of the CyberloQ Technologies (CLOQ) and Relevate AI agreement?

The agreement between CyberloQ Technologies and Relevate AI has a term of twelve months. After the initial term, the parties will review the arrangement and decide together whether to continue the agreement based on their experience and results.

How is the per-user commission from Relevate AI to CyberloQ Technologies (CLOQ) calculated?

Relevate AI charges $50 per user per month for its platform. CyberloQ earns a 10% commission per user on closed sales opportunities it initiates, which equals $5 per user per month, in addition to the fixed $750 monthly license fee from Relevate.

Filing Exhibits & Attachments

3 documents